Emergent BioSolutions
EBS
#6766
Rank
ยฃ0.47 B
Marketcap
ยฃ8.93
Share price
-1.24%
Change (1 day)
24.48%
Change (1 year)

Emergent BioSolutions (EBS) - Total liabilities

Total liabilities on the balance sheet as of September 2025 : ยฃ0.65 Billion

According to Emergent BioSolutions 's latest financial reports the company's total liabilities are ยฃ0.65 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Emergent BioSolutions - Total liabilities on balance sheet (from 2004 to 2025)

Total liabilities by year

Year Total liabilities Change
2024-12-31ยฃ0.72 B-21.57%
2023-12-31ยฃ0.92 B-37.32%
2022-12-31ยฃ1.47 B47.41%
2021-12-31ยฃ0.99 B-5.35%
2020-12-31ยฃ1.05 B11.53%
2019-12-31ยฃ0.94 B-1.59%
2018-12-31ยฃ0.95 B721.63%
2017-12-31ยฃ0.11 B-61.44%
2016-12-31ยฃ0.30 B18.97%
2015-12-31ยฃ0.25 B2.87%
2014-12-31ยฃ0.24 B197.11%
2013-12-31ยฃ83.33 M10.31%
2012-12-31ยฃ75.54 M-9.77%
2011-12-31ยฃ83.72 M1.97%
2010-12-31ยฃ82.11 M31.72%
2009-12-31ยฃ62.33 M-0.08%
2008-12-31ยฃ62.38 M21.1%
2007-12-31ยฃ51.51 M1.13%
2006-12-31ยฃ50.94 M116.4%
2005-12-31ยฃ23.54 M-1.98%
2004-12-31ยฃ24.01 M
2002-12-31ยฃ11.62 M-70.8%
2001-12-31ยฃ39.8 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Merck
MRK
ยฃ58.24 B 8,737.68%๐Ÿ‡บ๐Ÿ‡ธ USA
SIGA Technologies
SIGA
ยฃ21.09 M-96.80%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
ยฃ45.97 B 6,876.03%๐Ÿ‡ฌ๐Ÿ‡ง UK
Celldex Therapeutics
CLDX
ยฃ37.56 M-94.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
ยฃ86.74 B 13,062.78%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
ยฃ24.45 B 3,611.10%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Soligenix
SNGX
ยฃ2.77 M-99.58%๐Ÿ‡บ๐Ÿ‡ธ USA